Australia's Immutep hits record low on ceasing Phase III study of lung cancer treatment

Immutep

13/03/2026 02:32

** Shares of Immutep IMM.AX drop as much as 92.9% to a lifetime low of A$0.028

** Stock logs its largest intraday pct drop

** The biotechnology firm says independent data monitoring committee for co's TACTI-004 Phase III study for the treatment of non-small cell lung cancer has recommended the discontinuation of trial

** Says recommendation following a planned interim futility analysis in accordance with study protocol, based on review of available safety and efficacy data

** Adds enrolment in the study to be halted, co to implement orderly wind down of study

** More than 333.9 million shares change hands, 125.2 times the 30-day average

** Stock down 88.8% YTD, including the day's moves

 (Reporting By Sherry Philips)

 ((sherrymary.jacob@thomsonreuters.com;))